Although exact staging distributions and survival metrics vary, a consistent theme emerges: MMR-deficient patients under 60 typically present with fewer metastatic tumors (Stage IV) and demonstrate better overall survival. The gene discussed is MRC1; the disease is metastatic neoplasm.